



Recombinant Protein Technical Manual

**Recombinant Human Galectin-8/LGALS8 Protein
(GST Tag)(Active)**
RPES4606

Product Data:

Product SKU: RPES4606

Size: 50µg

Species: Human

Expression host: E. coli

Uniprot: AAF19370.1

Protein Information:

Molecular Mass: 62.7 kDa

AP Molecular Mass: 60 kDa

Tag: N-GST

Bio-activity: Measured by its ability to agglutinate human red blood cells. The ED50 for this effect is typically 0.2 µg/ml.

Purity: > 76 % as determined by reducing SDS-PAGE.

Endotoxin: Please contact us for more information.

Storage: Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Formulation: Lyophilized from sterile 50mM Tris, 0.1 M NaCl, pH 8.0

Reconstitution: Please refer to the printed manual for detailed information.

Application:

Synonyms: Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; Prostate Carcinoma Tumor Antigen 1; PCTA; LGALS8

Immunogen Information:

Sequence: Met 1-Trp 317

Background:

Galectin (Gal, GAL1), is a member of the galectins, a family of animal lectins ranging from *Caenorhabditis elegans* to humans, which is defined by their affinity for beta-galactosides and by significant sequence similarity in the carbohydrate-binding site. It is a homodimer with a subunit molecular mass of 14.5 kDa, which contains six cysteine residues per subunit. The cysteine residues should be in a free state in order to maintain a molecular structure that is capable of showing lectin activity. This endogenous lectin widely expressed at sites of inflammation and tumour growth, has been postulated as an attractive immunosuppressive agent to restore immune cell tolerance and homeostasis in autoimmune and inflammatory settings. On the other hand, galectin contributes to different steps of tumour progression including cell adhesion, migration and tumour-immune escape, suggesting that blockade of galectin might result in therapeutic benefits in cancer. Several potential glycoprotein ligands for galectin have been identified, including lysosome-associated membrane glycoproteins and fibronectin, laminin, as well as T-cell glycoproteins CD43 and CD45. Evidence points to Gal and its ligands as one of the master regulators of such immune responses as T-cell homeostasis and survival, T-cell immune disorders, inflammation and allergies as well as host-pathogen interactions.